International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 49
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page


A New RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet Dosage Form

Jitendra Debata, Sundeep Kumar, Sajal Kumar Jha and Amjad Khan

A new, simple, selective, accurate, rapid and precise reversed-phase high-performance liquid chromatographic technique of Dapagliflozin was established as per ICH Guidelines. RP-HPLC was performed on a Waters C18, 5 µm particle size, 25 cm × 4.6 mm i.d., with phosphate buffer and acetonitrile in the ratio of 60:40 v/v as a mobile phase and a flow rate of 1.0 ml min-1. UV detection was performed at 237 nm. Total run time was 6.0 min. The retention time of Dapagliflozin was found to be 3.461 minutes. Validation of the developed method was done as per USP and ICH guidelines. Method validation revealed that the method is rapid, accurate, precise, reliable, and reproducible. Linear calibration plots were obtained in the concentration range of 10-60 µg/ml for Dapagliflozin. Limit of detection were 0.02 µg/ml and limit of quantification were 0.06 µg/ml for Dapagliflozin. The high recovery and low coefficients of variation confirm the effectiveness of process in the dosage form. The validated method was successfully used for quantitative analysis of commercial available tablets.